^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Romvimza (vimseltinib)

    i
    Other names: DCC-3014, DCC 3014, DCC3014
    Associations

    News

    Trials
    Company:
    Ono Pharmaceutical
    Drug class:
    CSF-1R inhibitor, FMS kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    23d
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=22, Completed, Deciphera Pharmaceuticals, LLC | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2026 | Trial primary completion date: Jun 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    metformin • Romvimza (vimseltinib)
    1m
    Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update. (PubMed, Pharmacol Res)
    The following ten drugs received FDA approval in 2025 - avutometinib (inhibiting MEK1/2 in serous ovarian carcinomas), defactinib (blocking FAK in low grade serous ovarian carcinomas), delgocitinib (antagonizing the JAK family in hand eczema), mirdametinib (inhibiting MEK1/2 in type I neurofibromatosis), remibrutinib (blocking BTK in chronic spontaneous urticaria), rilzabrutinib (antagonizing BTK in chronic immune thrombocytopenia), sunvozertinib (blocking mutant exon 21 insertion EGFR NSCLC), taletrectinib (inhibiting mutant ROS1 in NSCLC), vimseltinib (blocking CSF1R in tenosynovial giant cell tumors), and zongertinib (antagonizing mutant HER2 in NSCLC). This article summarizes the physicochemical properties of all 94 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 45 of the 94 FDA-approved drugs have a least one Lipinski rule of five violation.
    FDA event • Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CSF1R (Colony stimulating factor 1 receptor)
    |
    EGFR mutation
    |
    Gomekli (mirdametinib) • Avmapki (avutometinib) • Hernexeos (zongertinib) • Fakzynja (defactinib) • Ibtrozi (taletrectinib) • Zegfrovy (sunvozertinib) • Rhapsido (remibrutinib) • Romvimza (vimseltinib)
    1m
    Investigating vimseltinib in tenosynovial giant cell tumors. (PubMed, Expert Opin Pharmacother)
    Furthermore, there is an absence of severe toxicities that have arisen with other agents in the TGCT treatment space, specifically liver failure. Vimseltinib is a favorable option for patients with TGCTs and further efforts to determine its place in the sequence of overall management are needed.
    Review • Journal
    |
    CSF1R (Colony stimulating factor 1 receptor)
    |
    Turalio (pexidartinib) • Romvimza (vimseltinib)
    2ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Completed, Deciphera Pharmaceuticals, LLC | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Romvimza (vimseltinib)
    2ms
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    metformin • Romvimza (vimseltinib)
    2ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Romvimza (vimseltinib)
    4ms
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    metformin • Romvimza (vimseltinib)
    4ms
    A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) (clinicaltrials.gov)
    P2, N=48, Recruiting, Deciphera Pharmaceuticals, LLC | N=36 --> 48
    Enrollment change
    |
    Romvimza (vimseltinib)
    5ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Romvimza (vimseltinib)
    6ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    Romvimza (vimseltinib)
    6ms
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    metformin • Romvimza (vimseltinib)
    6ms
    Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (clinicaltrials.gov)
    P1, N=32, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • Romvimza (vimseltinib)